Phase 3 Trial of SRG-514 in Triple Negative Breast Cancer Undergoing Surgery
A Phase 3 trial is underway to evaluate SRG-514, an intraoperative treatment for patients with triple negative breast cancer.
Company
Pharmaceutical intelligence for SURGE Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.